<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Acta Naturae</journal-id><journal-title-group><journal-title xml:lang="en">Acta Naturae</journal-title><trans-title-group xml:lang="ru"><trans-title>Acta Naturae</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-8251</issn><publisher><publisher-name xml:lang="en">Acta Naturae Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">10791</article-id><article-id pub-id-type="doi">10.32607/20758251-2009-1-3-108-120</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Cell Regulation of Proliferation and Differentiation ex vivo for Cells Containing Ph Chromosome in Chronic Myeloid Leukemia</article-title><trans-title-group xml:lang="ru"><trans-title>Cell Regulation of Proliferation and Differentiation ex vivo for Cells Containing Ph Chromosome in Chronic Myeloid Leukemia</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Grineva</surname><given-names>N I</given-names></name><email>nigrin27@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Akhlynina</surname><given-names>T V</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Gerasimova</surname><given-names>L P</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Manakova</surname><given-names>T E</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Sarycheva</surname><given-names>N G</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Schmarov</surname><given-names>D A</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Tumofeev</surname><given-names>A M</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Nydenova</surname><given-names>N M</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Kolosova</surname><given-names>L Yu</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Kolosheynova</surname><given-names>T I</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Kovaleva</surname><given-names>L G</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Kuznetsov</surname><given-names>S V</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Vorontsova</surname><given-names>A V</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Turkina</surname><given-names>A G</given-names></name><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">GU National Research Center for Hematology, Russian Academy of Medical Sciences</institution></aff><aff><institution xml:lang="ru"></institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2009-12-15" publication-format="electronic"><day>15</day><month>12</month><year>2009</year></pub-date><volume>1</volume><issue>3</issue><issue-title xml:lang="en">NO3 (2009)</issue-title><issue-title xml:lang="ru">№3 (2009)</issue-title><fpage>108</fpage><lpage>120</lpage><history><date date-type="received" iso-8601-date="2020-01-17"><day>17</day><month>01</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2009, Grineva N.I., Akhlynina T.V., Gerasimova L.P., Manakova T.E., Sarycheva N.G., Schmarov D.A., Tumofeev A.M., Nydenova N.M., Kolosova L.Y., Kolosheynova T.I., Kovaleva L.G., Kuznetsov S.V., Vorontsova A.V., Turkina A.G.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2009, Grineva N.I., Akhlynina T.V., Gerasimova L.P., Manakova T.E., Sarycheva N.G., Schmarov D.A., Tumofeev A.M., Nydenova N.M., Kolosova L.Y., Kolosheynova T.I., Kovaleva L.G., Kuznetsov S.V., Vorontsova A.V., Turkina A.G.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder xml:lang="en">Grineva N.I., Akhlynina T.V., Gerasimova L.P., Manakova T.E., Sarycheva N.G., Schmarov D.A., Tumofeev A.M., Nydenova N.M., Kolosova L.Y., Kolosheynova T.I., Kovaleva L.G., Kuznetsov S.V., Vorontsova A.V., Turkina A.G.</copyright-holder><copyright-holder xml:lang="ru">Grineva N.I., Akhlynina T.V., Gerasimova L.P., Manakova T.E., Sarycheva N.G., Schmarov D.A., Tumofeev A.M., Nydenova N.M., Kolosova L.Y., Kolosheynova T.I., Kovaleva L.G., Kuznetsov S.V., Vorontsova A.V., Turkina A.G.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://actanaturae.ru/2075-8251/article/view/10791">https://actanaturae.ru/2075-8251/article/view/10791</self-uri><abstract xml:lang="en"><p/></abstract><trans-abstract xml:lang="ru"><p>Cell regulation of Ph +cell proliferation and differentiation has been studied ex vivo in various chronic myeloid leukemia (CML) patients. The regulation is provided by alternation of effective stages of proliferation and maturation with inhibition of Ph+ cell proliferation by accumulating neutrophils under apoptosis blockage. The alternation of stages consists of switching stage 1 (effective proliferation) to stage 2 (effective maturation) and proceeds according to the 1/2 -1/2/1 or 2/1-2/1/2/1 schemes. The kinetic plots of alternations pass through control points of crossing plots, where the parameters of proliferation and maturation are equal. The indices of P/D efficiency (ratio of proliferation and maturation rates) are 1.06±0.23 and don’t depend on time, alternation order, or sources of Ph+ cells – CML patients. During stages alternation, conversely, the parameters of Ph + cell proliferation and maturation vary. The proliferation stages are characterized by increased proliferating cells content, a decreased number of neutrophils, and apoptosis induction. At the maturation stages, conversely, apoptosis is inhibited, the number of mature neutrophils increases, while immature Ph + cells decrease. High content neutrophils inhibit the proliferation of Ph + cells and impair their own maturation by inversion of maturation order, probably through a feedback mechanism. The regulation differences ex vivo reveal three types of Ph + cells from various individual CML patients, distinguished by the number and duration of alternating stages of proliferation and maturation. Ph + cells types 1 and 2 have one prolonged stage of effective proliferation or effective maturation with efficiency indices P/D 1 = 1-20 or P/D 2 ≤ 1. At the same time period, the proliferation and differentiation of the Ph + cells type 3 proceeds with repeated alternations of stages with P/D 1 = 1-4 or P/D 2 ≤ 1. Type 1 Ph + cells (~20%) were isolated from patients in advanced stages of CML, while Ph + cells types 2 and 3 (30 and 50% correspondingly) were isolated from CML chronic phase patients sensitive to chemotherapy.</p></trans-abstract><kwd-group xml:lang="en"><kwd>Regulation of Ph cell proliferation and Ph cell by mature cells</kwd><kwd>cultivation of hematopoietic Ph mononuclear cells</kwd><kwd>kinetics of Ph+cell proliferation and differentiation in vitro</kwd><kwd>Ph cells apoptosis</kwd><kwd>Ph cell distribution in cell cycle phases</kwd><kwd>Ph cell proliferation and differentiation efficacy</kwd><kwd>inversion of accumulation order for maturating neutrophils</kwd><kwd>chronic myeloid leukemia</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Abdulkadyrov K.M., Bessmeltsev C.C., Rukavitsin O.A. Chronic myelogenous leukaemia. S-Pb.: Special literature, 1998. 463 pp.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Haematological Guideline.- M. Newdiamed, Ed. A.I.Vorobiev. 2002. V.1, 280 pp 3.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Blood Patophisiology.- BINOM Publishers, Ed. Ph.D. Shiffman. 2000. 446 pp 4.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Deininger M.W.N., Goldman J.M., Melo J.V. // Blood. 2000. V. 96. P. 3343–3356.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Deininger M.W.N., Vieira S., Mendiola R., et al. // Cancer research. 2000. V. 60. P.2049–2055.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Medvedeva N.V. Chronic myelogenous leukaemia.- 50-th annual congress of American Haematological society. // Clinical oncohaematology, 2009. V. 2. №1. P. 85–88.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Melo J.V. // Blood. 1996. V. 88. P. 2375–2384.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Holyoake T.L., Jiang X., Eaves A.C., Eaves C.J. // Leukemia. 2002. V. 16. P. 549–558.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Holyoake T.L., Jiang X., Jorgensen H.G. et al. // Blood. 2001. V. 97. P. 720–728.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Jamieson C.H.M., Ailles L.E., Dylla S.J. et al. // New England J Medicine. 2004. V. 351. P. 657–667.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Jaiswal S., Traver D., Miyamoto T. et al. // Proc.Nat.Acad.. Sci. USA. 2003 V. 100. P. 10002–10007.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Passegue E., Jamieson C.H.M., Ailles L. E., Weissman I. L. // Proc.Nat.Acad. Sci. USA. 2003.V. 100. P. 11842–11849.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Strife A., Lambek C., Wisniewski D. et al. // Blood. 1983. V. 62. P. 389–397.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Strife A., Lambek C., Wisniewski, D. et al. // Cancer Res. 1988. V. 48. P. 1035–1041.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Era T., Witte O. N. // Proc. Nat. Acad. Sci. USA. 2000. V. 97. P. 1737–1742.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Guzman M.L., Jordan C.T. // Cancer Control. 2004. V. 11, -(№-)2. P. 97–104.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Bedi A., Zehnbauer B.A., Barber J. et al. //Blood. 1994. V. 83. P. 2038–2044.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Bedi A., Barber J. P., Bedi G.C et al. // Blood. 1995. V. 86. P. 1148–1158.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Brandford S., Rudzki Z., Walsh S. et al. // Blood. 2002. V. 99. P. 3472–3475.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Buckle A.M., Mottram R., Pierce A. et al. // Mol. Med. 2000.V. 6. P. 892–902.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Clarkson B., Strife A., Perez A. et al. // Leukemia - Limphoma. 1993. V. 11. P. 81–100.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Clarkson B., Strife A. // Leukemia. 1993. V. 7. P. 1683–1721.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Coppo P., Bonnet M L., Dusanter-Fourt I. et al. // Oncogene. 2003. V. 22(26). P. 4102–4110.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Traycoff C.V., Haistead B., Rice S. et al. // Brit. J. Haematology. 1998. V. 102. P.759 - 767</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Lotem J., Sachs L. // Leukemia. 1996. V. 10. P. 925–9313.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Lugo T.G., Pendergast A.M., Muller A.J., Witte O.N. // Science. 1990. V. 247. P. 1079–1082.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Cortez D., Kadlec L., Pendergast A.M. // Mol. Cell. Biology. 1995. -(№-)10. P. 5531–5541.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Primo D., Flores J, Quijano S. et al. // Brit.J. Haematology. 2006. V. 135. P. 43–51.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Amarante-Mendes G.P., Naekyung Kim C., Liu L. et al. // Blood. 1998. V. 91. P. 1700–1705.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Selleri C., Maciejewski J.P., Pane F., et al. // Blood. 1998. V. 92. P. 981–989.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Sherbenou D.W., Hantschel O., Turaga L. et al. //Leukemia. 2008. V. 22. P. 1184–1190.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Stoklosa T., Poplawski T., Koptyra M., et al. // Cancer Res. 2008. V. 68. P. 2576–2580.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Akhynina T.V., Gerasimova L.P., Sarkisyan G.P. et al. // Cytology. 2007. V. 49. P. 889–900.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Abramov M.G. Haematological album. M: Medicine, 1985.344 pp.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Gerasimova L.P., Manakova T.E., Akhynina T.V. et al. // Russian Journal of Biotherapy. 2002. V.1, № 4. P. 29–38</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Pinegin B.V., Yiarilin A.A., Simonova A.V. et al. // Apoptosis evaluation of human peripherial blood activated lymphocytes by cytofluorimetric method with propidium jodide // In: Use of flow cytofluorimetry for estimation of human immune system functional activity. М., МH. RF, 2001. P. 48–53</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Shmarov D.A., Kosinets G.I. Methods of cell cycle analysis by flow cytofluorimetry // In: Laboratorial-clinical meaning of blood analysis by flow cytofluorimetry. М.: Medical Informational Agency, 2004.P. 49–65</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Dean P.N. // Cell Tissue Kinet. 1980. V. 13. P. 299–302.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Grineva N.I., Barishnicov A.Ju., Gerasimova L.P. et al. // Russian Journal of Biotherapy. 2007. V.6, № 2. P. 21–32</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Kosinets G.I., Kotelnicov V.M. // Soviet Medicine. 1983. № 4. P. 3–77</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Kotelnicov V.M., Kosinets G.I., Kasatkina V.V., Kovalevskaya N.P. Kinetics of granulocytepoiesis. // In: Kinetic aspects of haemopoiesis. Tomsk State University. 1982. P.149–211.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Golde D.W., Cline M.J. // New Engl. J. Med. 1973. V. 288. P. 1083–1086.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Vladimirskaya E.B. Mechanisms of blood cells apoptosis. // Laboratorial Medicine. 2001. № 4. P. 47–54.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Vladimirskaya E.B. Apoptosis and its role in the development of tumor growth. // In: Biological basis of antitumour therapeutics. М.: Agat –Med, 2001. P. 5–32</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Dublez L., Eymin B., Sordet O. et al. // Blood. 1998. V. 91. P. 2415–2422.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Goldman J. M., Th’ng K.G., Catovsky D., Galton D.A.D. // Blood. 1976. V. 47. P.381–388.</mixed-citation></ref></ref-list></back></article>
